Corcept Therapeutics is trading at $76.04 (-7.19%) after management reiterated 2026 revenue guidance of $1.1–$1.2 billion rather than raising it, a source of investor disappointment.
- Third-quarter results released November 3 included revenue of $340.5 million, above analyst estimates, and adjusted EPS of $1.01.
- Lifyorli sales rose 92% sequentially to $91.4 million, but the strong launch and earnings beat did not offset concerns about the unchanged outlook.